focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,797.00
Bid: 1,796.00
Ask: 1,797.00
Change: -15.50 (-0.86%)
Spread: 1.00 (0.056%)
Open: 1,792.50
High: 1,802.00
Low: 1,792.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-African Union to start talks with WHO on malaria vaccine rollout

Thu, 07th Oct 2021 15:04

(Adds quotes from mother of a vaccinated child)

By Maggie Fick

NAIROBI, Oct 7 (Reuters) - Africa will start talks with the
World Health Organization about getting the first approved
malaria vaccine to the continent as soon as possible, the
African Union's top health official said on Thursday, amid calls
for funding for drugs beyond COVID-19.

John Nkengasong spoke a day after the WHO said RTS,S - or
Mosquirix - developed by British drugmaker GlaxoSmithKline
should be widely given to children in Africa.

Experts said the recommendation was potentially a major
advance against a disease that kills a quarter of a million
African children each year.

"We will be engaging with GAVI (the vaccine alliance) and
WHO in the coming days to understand first of all the
availability of this vaccine," Nkengasong, director of the
Africa Centres for Disease Control and Prevention (Africa CDC),
told an online news conference.

Calling malaria a major killer in Africa, Nkengasong urged
donors not to play a zero-sum game "where we fund COVID vaccines
and neglect malaria vaccines".

He said it was unclear when the vaccine will be accessible
to the many African countries where malaria is endemic because
the cost per dose is not known and it is not clear how quickly
production can be scaled up.

GSK has to date committed to produce 15 million doses of
Mosquirix annually up to 2028 at a cost of production plus no
more than 5% margin.

A global market study led by the WHO this year projected
demand for a malaria vaccine would be 50 to 110 million doses
per year by 2030 if it is deployed in areas with moderate to
high transmission of the disease.

Mosquirix has been 30 years in the making. Since 2019, 2.3
million doses of Mosquirix have been administered to infants in
Ghana, Kenya and Malawi in a large-scale pilot programme
coordinated by the WHO.

Phoebe Wetende, a 23-year-old a hairdresser who lives in
Yala area in Siaya county in Western Kenya told Reuters she had
enrolled her 2-year-old daughter in the trial programme because
her family had suffered frequent malaria infections.

Her daughter received her fourth and last dose at Yala
Sub-County Hospital on Thursday.

"When I was young, my family was prone to malaria
attacks...I could miss school because I am admitted in
hospital," she said. "My aunt suffered cerebral malaria, and it
scared us. She is still under treatment."

Nkengasong noted that by the end of 2021, malaria will
likely have killed many more people in Africa, especially
children, than COVID-19 has this year on the continent.

GAVI will consider in December whether and how to finance
the vaccination programme.
(Reporting by Maggie Fick
Editing by Frances Kerry)

More News
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.